Estrogen and progesterone coupled with locally produced signaling molecules are essential for embryo implantation. However, the hierarchical landscape of the molecular pathways that governs this process remains largely unexplored. Here we show that the protein tyrosine phosphatase Shp2, a positive transducer of RTK signaling, is predominately localized in the nuclei in the periimplantation mouse uterus. Uterine-specific deletion of Shp2 exhibits reduced progesterone receptor (PR) expression and progesterone resistance, which derails normal uterine receptivity, leading to complete implantation failure in mice. Notably, the PR expression defects are attributed to the limited estrogen receptor α (ERα) activation in uterine stroma. Further analysis reveals that nuclear Shp2, rather than cytosolic Shp2, promotes the ERα transcription activity. This function is achieved by enhancing the Src kinasemediated ERα tyrosine phosphorylation, which facilitates ERα binding to Pgr promoter in an ERK-independent manner in periimplantation uteri. Besides uncovering a regulatory mechanism, this study could be clinically relevant to dysfunctional ERα-caused endometrial disorders in women.
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Shp2 | ERK signaling | Src kinase | estrogen receptor | uterine receptivity S uccessful implantation requires synchronization between an implantation-competent blastocyst and a receptive uterus. In humans, natural conception per cycle is poor (∼30%), and ∼75% of failed pregnancies are considered to be due to implantation failure (1) . One-third of implantation failure is attributed to the embryo itself, whereas the remaining two-thirds appear to result from inadequate uterine receptivity (2) . The endometrium enters into a receptive stage for blastocyst implantation only in a restricted time period termed "implantation window," which is dominated by precisely regulated proliferation and differentiation of endometrial epithelium and stroma under the influence of progesterone and estrogen (3) .
Estrogen and progesterone bind to the estrogen receptor (ER) and progesterone receptor (PR), respectively, coupled with specific cofactors to endure the optimal functions. The activity of these nuclear receptors is also regulated at the posttranslational level by various modifications, such as phosphorylation, which can influence the protein stability, interaction with the cofactors and DNA binding affinity. So far, a wide range of nuclear receptor cofactors have been identified to ensure the normal ER transcriptional activation, such as the well-known steroid receptor coactivator (SRC) family members, which bind with ERα in the chromatin to recruit the histone acetyltransferase p300 (P300) for transcriptional activation (4) (5) (6) . It is conceivable that ordered and combinatorial recruitment of cofactors at a specific target promoter after ERα binding to DNA sequence was essential to ensure target gene transcription. Recent evidence shows that nuclear receptor coactivator 6 is essential for embryo implantation by maintaining the appropriate level and activity of uterine ERα. Its deficiency induces aberrantly increased ERα protein level and thus hyperactivation of estrogen-ER signaling (7) . Because either hyper-or hypoactivation of estrogen-ER signaling is associated with pregnancy disorders, such as recurrent implantation failure and endometriosis in women, it is extremely important to further explore the underlying mechanism governing normal ER transcriptional activation in the uterus during early pregnancy.
Src homology 2 domain containing protein tyrosine phosphatase (SHP2), encode by the gene Ptpn11, is a ubiquitously expressed protein tyrosine phosphatase, and its dysregulation is associated with malignant neoplasms and developmental disorders (8, 9) .
Significance
Dysfunctional uterine receptivity is responsible for approximately 70% of implantation failures. This periimplantation event is dominated by ovarian hormones progesterone and estrogen functioning through their corresponding receptors, PR and ER, coupled with locally produced signaling molecules. However, the hierarchical landscape of the molecular pathways that govern this process remains largely unexplored. Here we show that Shp2, a classic cytoplasmic protein, is mainly located in the nuclei in uterine cells at periimplantation. Further investigation revealed that nuclear Shp2 enhances the Src kinase-mediated ERα tyrosine phosphorylation, facilitates ERα binding to Pgr promoter, and thus promotes the ERα transcription activity in periimplantation uteri. Our findings have high clinical significance in identifying novel therapeutic targets for the aberrant uterine receptivity and implantation failure.
Structurally, Shp2 contains two N-terminally located Src-homology 2 domains (N-SH2 and C-SH2), a central phosphotyrosine phosphatase (PTP) domain and a C-terminal tail with tyrosyl phosphorylation sites and a proline-rich motif. Shp2 has been well defined as a positive cytoplasmic regulator for receptor protein tyrosine kinases (RTKs) in mediating cellular response to hormones, growth factors, and cytokines. Systemic deletion of Shp2 in mice results in embryonic lethality shortly after implantation, due to defective extracellular signal-regulated kinase (ERK) activation and the resulted death of trophoblast stem cells (10) . However, it remains largely unknown whether uterine Shp2 is physiologically involved in regulating early pregnancy events. Because various RTK-coupled cytokines and growth factors, such as leukemia inhibitory factor (11), Interleukin 11 (12) , and EGF family growth factors (13, 14) , are essential for normal embryo implantation, we speculated that Shp2 could be an important player in directing normal early pregnancy events.
In the current study, using multiple genetic and molecular approaches, we provided strong evidence that Shp2 is essential for normal uterine receptivity and embryo implantation in an unexpected ERK-independent manner. Uterine-specific deletion of Shp2 dramatically limits estrogen receptor ERα transcriptional activity, leading to impaired uterine receptivity and complete implantation failure. In searching for the underlying molecular causes, we were surprised to find that nuclear Shp2 promotes ERα transcription activity by enhancing the Src kinase-mediated ERα tyrosine phosphorylation, which facilitates ERα binding to Pgr promoter in the periimplantation uteri.
Results

Shp2 Exhibits Nuclear Localization in Mouse Uteri at Periimplantation.
To address the pathophysiological significance of Shp2 during early pregnancy, we first examined mouse uterine expression pattern of Shp2 at periimplantation stage. As revealed by in situ hybridization, whereas Ptpn11 was nearly undetectable in the uterus on day 1 of pregnancy (D1, day 1 = vaginal plug positive), its expression was intensely observed in subepithelial stromal cells on D4 (Fig. 1A) . With the onset of embryo implantation on D5, Ptpn11 was highly up-regulated in both the epithelial and stromal cells around the implanting blastocyst (Fig. 1A) . With the initiation and progression of decidualization on D6-8, Ptpn11 expression expanded into the entire decidual bed (Fig. 1A) . This dynamic expression pattern suggests that Shp2 could be an important player during the periimplantation stage.
We next analyzed Shp2 protein distribution in periimplantation uteri by immunohistochemistry analysis. Consistent with its RNA expression pattern, Shp2 protein was highly expressed in uterine stroma (Fig. 1B) . It was worthy to note that Shp2 was also localized to nuclei in proliferating and decidualizing stromal cells on D4-8 of pregnancy (Fig. 1B) . This finding was further confirmed by the Western blot analysis showing a higher Shp2 expression in nuclear extracts (Fig. 1C) . These observations point toward a potential nuclear-related function of Shp2 in the uterus during early pregnancy. ). As illustrated in Fig. 2 A- 2 F-H) . These results clearly indicate that uterine Shp2 is indispensable for normal embryo implantation.
Shp2 Depletion Derails Normal Uterine Receptivity Depicting
Progesterone Resistance. To portray the uterine lumen morphology at periimplantation, we performed immunofluorescence staining of cytokeratin (an epithelial marker) and Ki-67 (a cell proliferation marker). We observed that Shp2 d/d uteri exhibited a defective luminal closure characterized by increased uterine epithelial branches (Fig. 3A) . Moreover, Ki-67 staining analysis revealed an aberrant epithelial proliferation accompanied by a dramatically decreased stromal cell division in Shp2 d/d mice ( Fig.  3 B and C). These cellular defects indicate an abnormal uterine receptivity upon Shp2 deficiency.
Because progesterone and estrogen are the principle determinants of uterine receptivity in mice, we next measured serum levels of progesterone (P 4 ) and estradiol-17β (E 2 ) in D4 Shp2 f/f and Shp2 d/d female mice. As shown in Fig. S1 A and B, we observed comparable circulating levels of E 2 and a slight decreased level of P 4 . Immunohistochemistry staining revealed that the corpus luteum expressed lower levels of Shp2 in comparison with the developing follicles (Fig. S1C) . However, depletion of luteal Shp2 exerted no apparent influence on the expression of progesterone biosynthetic enzymes, cytochrome P450 cholesterol side-chain cleavage enzyme, and 3β-hydroxysteroid dehydrogenase II (Fig. S1C ). To further test whether this slightly reduced progesterone secretion was the main cause for implantation failure in Shp2 d/d females, we supplied P 4 in the null mice for 3 consecutive days starting on D3. However, P 4 supplementation failed to restore embryo implantation in Shp2 d/d mice (Fig. S1D ). This result indicates that implantation failure in Shp2 d/d mice is intrinsic to uterine dysfunctions. To reveal the molecular basis of phenotypic defects in the absence of uterine Shp2, we then analyzed the expression of implantationrelated genes in D4 uteri by qPCR and in situ hybridization. As shown in Fig. 3 D and E, whereas the epithelial estrogen-regulated genes including mucin 1 (Muc1) and lactotransferrin (Ltf) were aberrantly induced in Shp2 d/d mice, all progesterone-targeting genes, such as amphiregulin (Areg), homeobox A10 (Hoxa10), heart and neural crest derivatives expressed 2 (Hand2), and chicken ovalbumin upstream promoter transcription factor 2 (Coup-tfII, also known as Nr2f2) were down-regulated in Shp2 d/d uteri. This abnormal expression profile of implantation-related genes was well coincident with abnormal epithelial versus stromal proliferation ( Fig. 3 B and  C) , indicating an impaired progesterone activity and loss of antagonistic influence of progesterone-PR signaling on estrogenstimulated epithelial proliferation in Shp2 d/d uteri. However, this molecular and cellular abnormality was not due to above-mentioned reduced circulating progesterone level, because progesterone supplementation failed to restore normal uterine receptivity marker gene expression (Fig. S1E ) and uterine epithelial versus stromal proliferation in Shp2 d/d uteri (Fig. S1F ). Similar observation of enhanced uterine epithelial proliferation with reduced stromal proliferation can be mimicked in Shp2 f/f mice by the treatment of progesterone antagonist RU486 (Fig. S2) , phenocopying the progesterone resistance in mice lacking uterine Shp2. uteri. As shown in Fig. 4 A-C, ERα was comparably expressed even in the absence of uterine Shp2. In contrast, the expression of PR (encoded by Pgr) was significantly decreased in Shp2
uteri. Further localization analysis revealed that the stroma PR was severely decreased in Shp2 d/d uteri (Fig. 4D) . As the stroma Pgr is induced by the estrogen-ER signaling, to explore whether this decreased Pgr expression is due to hampered estrogen activities, we further analyzed some other ER target genes, including insulin-like growth factor 1 (Igf1) and erythroblastosis oncogene B 1 (Erbb1). They also displayed decreased expression in the Shp2 (Fig. 4D) . This interesting finding suggests that progesterone resistance from Shp2 deficiency is secondary to impaired uterine responsiveness to estrogen, regardless of normal circulating estrogen level and uterine ERα expression in null mice.
To further confirm that this reduced PR expression in uterine stroma was due to hampered estrogen activities upon Shp2 deletion, we used an ovariectomized mouse model. As illustrated in Fig. 4E , all tested ER target genes, including Pgr, Igf1, vascular endothelial growth factor (Vegf), and Erbb1 were expressed at significantly lower levels at 6 h after estrogen challenge in ovariectomized Shp2 d/d uteri compared with that in Shp2 f/f females. In situ hybridization analysis further revealed that the induction of ER-targeting gene-like Pgr was not noted in Shp2
stroma after estrogen stimulation (Fig. 4F) . These results reinforce the notion that Shp2 deficiency compromises uterine estrogen responsiveness and thus its target gene expression including Pgr in uterine stroma.
Because Shp2 is known as a positive signal transducer in ERK pathway, to test whether Shp2 would function through ERK pathway to regulate ERα activity in the uterus, we next examined the expression of p-ERK1/2 (activated form of ERK1/2) in D4 Shp2 f/f and Shp2 d/d uteri. Unexpectedly, p-ERK1/2 levels remained unaltered in Shp2 d/d uteri ( Fig. S3 A and B) , suggesting that Shp2 may function through an ERK-independent manner to ensure ER activation during uterine receptivity establishment.
To further exclude the possibility that Shp2 ensure the ERα activity via ERK pathway, we treated the human endometrial Ishikawa cells with a specific MEK1/2 inhibitor, U0126. The data demonstrated that ERK inhibition exerts apparently no influence on ERα transcriptional activation, because E 2 can significantly induce ER-targeting gene PGR expression even in the presence of U0126 (Fig. S3C ).
Nuclear Shp2 Rather than Cytosolic Shp2 Is Required for Normal ERα
Activation. To further delineate the molecular basis of Shp2 on ERα, we next used a human endometrial Ishikawa cell line for in vitro study. Because Ishikawa cells expressed high levels of endogenous SHP2 (Fig. 5 A and B) , we generated a SHP2 null mutant Ishikawa cell line by CRISPR/Cas9 strategy ( Fig. S4 A-C). As shown in Fig. 5 A and B, we found the expression of SHP2 was completely deleted in SHP2 null cells. Besides, the ERK1/2 activation in response to amphiregulin (Areg) was also abolished in the knockout cells (Fig. S4D ). Most importantly, SHP2 deficiency in Ishikawa cells significantly hampered estrogeninduced target gene expression, such as PGR and IGF1, whereas transfection with the full-length wild-type SHP2 (SHP2-WT) can rescue this defect (Fig. 5C ). These observations confirm the findings in Shp2 d/d mouse uteri, proving that SHP2 is essential for normal ER transcriptional activity. Because we observed a high level of Shp2 within the nucleus, to test whether the facilitating effect of Shp2 on ERα activation would depend on its nuclear localization, we next introduced a nucleus-excluded form of HA-tagged SHP2 (SHP2-NES) that contained a potent nuclear export sequence fused to the carboxyl terminus of original SHP2 (15) . As expected, whereas the SHP2 mutant Ishikawa cell line transfected with HA-labeled SHP2-WT exhibited both cytosolic and nuclear localization, the null mutant cells transfected with SHP2-NES showed prominent cytosolic accumulation of SHP2 (Fig. 5D) . Furthermore, whereas ERK1/2 activation in response to amphiregulin (Areg) could be largely restored by both SHP2-NES and SHP2-WT in knockout Ishikawa cells (Fig. 5E ), SHP2-NES, unlike SHP2-WT, failed to rescue E 2 -induced ERE (estrogen-responsive element) response in mutant cells (Fig.  5F ). These findings indicate that nuclear Shp2 rather than cytosolic Shp2 is required for normal ERα activity.
Nuclear Shp2 Enhances ERα Phosphorylation via Src Kinase Activation,
Facilitating Its Binding to Pgr Promoter. Because ERα and Shp2 both exhibited nuclear localization in the uterus, we tested the possibility of whether Shp2 could interact with ERα. Coimmunoprecipitation analysis revealed that Shp2 can physically interact with ERα in D4 receptive uteri as well as in Ishikawa cells (Fig. 6 A and  B) . To further define which part of SHP2 mediated the interaction with ERα, we generated truncation mutants of SHP2 harboring PTP domain deletion (ΔPTP) or SH2 domain deletions (ΔSH2). Using coimmunoprecipitation analysis, we found, whereas the ΔSH2 mutant containing PTP domain only exhibited barely detectable binding affinity with ERα, ΔPTP mutant with intact SH2 domains showed significantly higher binding affinity (Fig. 6C) . These findings suggest that SH2 domains are the key regions physically interacting with ERα. However, neither the ΔSH2 nor ΔPTP could reverse the defective E 2 -ER response in the absence of intact SHP2 (Fig. S5) . The inability of inactive SHP2 with phosphatase point mutation to restore the E 2 -ER response further suggests that the phosphatase activity of SHP2 is also critical for promoting the ER activity.
As a transcription factor, nuclear-located ERα would bind to the DNA of target genes, we wonder whether Shp2 would translocate to the chromatin with ERα. The whole cell lysates were fractionated into chromatin and soluble fractions. As shown in Fig. 6D , Shp2 was detected in the soluble compartment, but not in the chromatin fraction, whereas the ERα was positive both in the soluble and chromatin fractions. The ChIP-qPCR analysis further confirmed the absence of Shp2 in the chromatin fraction. There is no significant enrichment of Shp2 on the Pgr promotor compared with the IgG, whereas ERα indeed can bind within this element (Fig. 6E) . Next, we asked whether the Shp2 could influence the ER protein modification before the ERα recruitment to the DNA, particularly the ERα Tyr phosphorylation that has been reported to regulate the ERα activity (16) . Because Shp2 is a protein tyrosine phosphatase, we speculated that Shp2 deficiency would lead to an increased Tyr phosphorylation of ERα in case ERα is a direct substrate of Shp2. By contrast, after E 2 challenge, a decreased Tyr phosphorylation level of ERα was observed both in vivo and in vitro in the absence of Shp2 (Fig. 6 F and G and Fig. S6 A and B) , implying that ERα is not a direct substrate of Shp2, and there is another upstream kinase for ERα phosphorylation modification.
The phosphorylation of ERα has been reported to influence the ER binding to DNA and interaction with the cofactors such as SRC and P300. Indeed, the ChIP-qPCR analysis revealed that binding of ERα to Pgr promotor was severely dampened in the absence of Shp2 both in D4 uteri and E 2 -challenged ovariectomized mouse uteri (Fig. S7 A and B) . Moreover, even the cofactors SRC1 and P300 were normally expressed in the Shp2 knockout uteri (Fig. S7C) , the interaction between ERα and these cofactors was markedly reduced in the Shp2 null uteri (Fig.  S7D) . These findings suggest that uterine Shp2 deficiency attenuates ERα Tyr phosphorylation, and decreases its recruitment to target genes and interaction with the cofactors, leading to impaired uterine estrogen responsiveness.
Because Src kinase was reported to influence the ERα Tyr phosphorylation, we thus examined the expression of Src and its activated phosphorylated form (p-Y416). As shown in Fig. 6H , the protein exhibited both the cytoplasmic and nuclear localization. Previous studies suggest that Shp2 promotes c-Src activation by directly or indirectly controlling phosphorylation of Cterminal inhibitory phosphorylation site Tyr527. We then used the substrate trapping strategy to define whether the Src kinase is a direct substrate of Shp2. Unlike ERα, the Src kinase preferentially interacted with the trapping mutant Shp2, suggesting the Src rather than ERα is a potential substrate of SHP2 phosphatase (Fig. 6I) . Moreover, the inhibitory Y527 phosphorylation form of Src was more prominent in the SHP2 knockout cells (Fig. 6J) .
We then analyzed the consequence of Src kinase inhibition on ER activation. As shown in Fig. 6K , pretreatment with SRC inhibitor saracatinib abolished estrogen-evoked Src activation, as demonstrated by decreased level of pY416 and abnormal high level of inhibitory Y527 phosphorylation. This inhibitor pretreatment also substantially impaired the ERα Tyr phosphorylation (Fig. 6L) . Moreover, Src kinase inhibition also abolished the E 2 -induced target gene expression (Fig. 6M) , faithfully mimicking the Shp2 knockout phenotype. Together, these data support the notion that Shp2 promotes the ERα transcriptional activity by enhancing the Src kinase-mediated ERα tyrosine phosphorylation.
Discussion
In our study, we observed a dramatically decreased PR expression in the stroma in the absence of uterine Shp2, associated with attenuated stromal growth and aberrant epithelial overproliferation, indicating that Shp2 is essential for normal stromal PR expression and epithelial-stromal interactions during uterine transformation for receptivity. This observation is consistent with previous observations that insufficient PR signaling hampers the intimate stromal-epithelial crosstalk and thus uterine receptivity (17, 18) . However, it was a meandering path for us to realize and confirm that this functional progesterone resistance in the absence of uterine Shp2 is seeded by the significantly decreased level of stromal PR protein, which results from an impaired estrogen-ERα activity in stroma. It is also worthy to note that the epithelial estrogen-ER signaling seems normal, which is consistent with the low expression level of Shp2 in epithelium. This finding suggests a cell context-specific function of Shp2 in ensuring the ERα activity and/or the disappearance of stromal PR antagonistic influence. Meanwhile, there is no apparent decrease of epithelial PR expression in Shp2 d/d uteri at periimplantation, confirming the hampered ER activity in the absence of Shp2, because it is the stroma estrogen-ERα signaling that suppresses the epithelial PR expression (19) . In searching for the underlying molecular mechanisms, we further demonstrate that Shp2 in the nucleus can enhance the Src kinase-mediated ERα tyrosine phosphorylation, facilitate ERα binding to target gene promoter, and thus promote the ERα transcription activity in periimplantation uteri (Fig. S8) . In fact, there was evidence showing that Shp2 can translocate into the nucleus to participate in DNA damage-induced apoptotic responses (20, 21) , forming a complex with STAT5 for regulation of target gene transcription (22) or interacting with telomerase reverse transcriptase involved in replicative senescence (23) . Most recent studies also showed that nuclear Shp2 can dephosphorylate parafibromin influencing Wnt targeting-gene activation (24, 25) . In our study, we found that Shp2 mainly functions in the nucleus in an enzyme activity-dependent way and interacts with the ERα mainly through SH2 domain. However, this interaction is not equivalent to enzyme-substrate interaction and therefore does not necessarily suggest that ER is a substrate candidate of Shp2. Indeed, the Shp2 enhances the Tyr phosphorylation of ER by facilitating the Src kinase activity through dephosphorylation of an inhibitory Tyr in Src kinase. Whereas the Src kinase is broadly recognized as a cytoplasmic protein, recent reports also observed the nuclear function of this kinase that was activated by Shp2 through dephosphorization of the inhibitory p-Tyr site for DNA damage response (26) .
Nonetheless, besides uncovering a function and mechanism of nuclear Shp2 in ensuring normal ERα transcriptional activation conducive to uterine receptivity and implantation, our findings have high clinical significance, because dysfunctional ERα activity is often associated with multiple endometrial disorders.
Materials and Methods
Animals and Treatments. Shp2 flox/flox mice were generated as previously described (27) . Uterine-specific knockout mice were generated by crossing Shp2 flox/flox mice with Pgr Cre/+ mice. All mice were housed in the animal care facility of Xiamen University, in accordance with the guidelines for the care and use of laboratory animals. Experimental procedures to treat mice and analyze implantation sites are provided in SI Materials and Methods.
In Situ Hybridization. In situ hybridization was performed as previously described (28) . Sections hybridized with the sense probes served as negative controls. Mouse-specific cRNA probes for Ptpn11, Ltf, Muc1, Areg, Pgr, and Igf1 were used for hybridization.
Immunostaining. Immunohistochemistry and immunofluorescence analysis were performed as described previously (29) .
Western Blot. Protein extraction and Western blot analysis were performed as described previously (28) . Insoluble chromatin fraction and soluble fraction were extracted according to the previous methods (30) . Uncropped images of immunoblots are provided in Fig. S9 .
Real-Time RT-PCR Analysis. Quantitative RT-PCR was performed as described (31) . All primers for real-time PCR are listed in Table S1 . All real-time PCR experiments were repeated at least three times.
Generation of SHP2 Knockout Human Ishikawa Cell Line. Ishikawa cells were maintained at 37°C in an atmosphere of 5% CO 2 /95% air in DMEM supplemented with 10% (vol/vol) FBS. SHP2-deficient Ishikawa cells were generated by CRISPR/Cas9-mediated genome engineering.
Coimmunoprecipitation and Chromatin Immunoprecipitation. Coimmunoprecipitation (co-IP) and chromatin immunoprecipitation (ChIP) analysis were performed as previously described (31) . Immunoprecipitated proteins were separated by SDS/PAGE and detected by immunoblotting using the respective antibodies. Specific primers were used to detect immunoprecipitated chromatin fragments, as well as input chromatin (Table S1 ).
Statistical Analysis. All data are presented as mean ± SEM. Each experiment included at least three independent samples. Comparison between two groups was made by unpaired Student's two-tailed t test, and comparisons among three groups or more were made by one-way ANOVA test. P < 0.05 was considered to indicate a significant result.
